Literature DB >> 29651213

Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.

Abdoljalal Marjani1, Aman Mohammad Gharanjik2.   

Abstract

Cytochrome P450 2C9 (CYP2C9) is involved in metabolism of many important drugs and its genotype variations is thought to affect drug efficacy and the treatment process. The aim of this study was to assess the distribution of CYP2C9 allele and genotypic variants in Sistani ethnic group, living in Gorgan, South East of Caspian Sea and North East of Iran. This study included 140 Sistani, referred to the health center of Gorgan. CYP2C9 genotyping was carried out by polymerase chain reaction-restriction fragment length polymorphism technique. The allele frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 was 76.1, 16.1 and 7.8%, respectively. The frequency of CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes was 53.9, 22.1, 11.4, 2.9, 4.3% and nil, respectively. In this study the genotypic variations of the CYP2C9 allele among the Sistani ethnic group was investigated and great differences were observed in comparison to other populations. Our findings suggest that different genotypes of CYP2C9 may influence the pharmacokinetics of some drugs. More studies on the pharmacokinetic effects of CYP2C9 genotypes may help physicians choose optimal dosage of some drugs for treatment and prevention of their side effects. Since different ethnic groups from all over the world use medications, it suggests to investigate the pharmacokinetic effects of CYP2C9 genotypes in different populations.

Entities:  

Keywords:  Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP); Polymorphism of CYP2C9; Sistanee ethnic group

Year:  2017        PMID: 29651213      PMCID: PMC5891452          DOI: 10.1007/s12291-017-0660-7

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  35 in total

1.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

2.  Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.

Authors:  Z F Yang; H W Cui; T Hasi; S Q Jia; M L Gong; X L Su
Journal:  Genet Mol Res       Date:  2010-09-14

3.  Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies.

Authors:  Csilla Sipeky; Lilla Lakner; Melinda Szabo; Istvan Takacs; Viola Tamasi; Noemi Polgar; Andras Falus; Bela Melegh
Journal:  Blood Cells Mol Dis       Date:  2009-06-21       Impact factor: 3.039

4.  VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

Authors:  Kyoko Obayashi; Katsunori Nakamura; Junichi Kawana; Hiroyasu Ogata; Kazuhiko Hanada; Masahiko Kurabayashi; Akira Hasegawa; Koujirou Yamamoto; Ryuya Horiuchi
Journal:  Clin Pharmacol Ther       Date:  2006-08       Impact factor: 6.875

5.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Authors:  R S Kidd; A B Straughn; M C Meyer; J Blaisdell; J A Goldstein; J T Dalton
Journal:  Pharmacogenetics       Date:  1999-02

6.  CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.

Authors:  David L Veenstra; David K Blough; Mitchell K Higashi; Frederico M Farin; Sengkeo Srinouanprachan; Mark J Rieder; Allan E Rettie
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

Review 7.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.

Authors:  Kostas Arvanitidis; Georgia Ragia; Maria Iordanidou; Sofia Kyriaki; Athanasia Xanthi; Anna Tavridou; Vangelis G Manolopoulos
Journal:  Fundam Clin Pharmacol       Date:  2007-08       Impact factor: 2.748

9.  Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.

Authors:  Tomoko Ota; Yuka Kamada; Mariko Hayashida; Kyoko Iwao-Koizumi; Shigenori Murata; Kenji Kinoshita
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  1 in total

Review 1.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.